Hua Medicine (Shanghai) Ltd.
HUMDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | -3.10 | 0.39 | 0.75 |
| FCF Yield | -39.26% | 28.19% | -8.58% | -7.98% |
| EV / EBITDA | -1.13 | -10.94 | -15.51 | -11.80 |
| Quality | ||||
| ROIC | -26.87% | -19.08% | -27.02% | -39.57% |
| Gross Margin | 48.74% | 48.78% | 43.69% | 0.00% |
| Cash Conversion Ratio | 1.67 | -4.21 | 1.13 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 144.07% | – | 26.65% | -100.00% |
| Free Cash Flow Growth | -147.96% | 441.46% | 24.21% | -629.35% |
| Safety | ||||
| Net Debt / EBITDA | 4.06 | 7.74 | 2.34 | 1.95 |
| Interest Coverage | -40.96 | -36.56 | -72.84 | -81.14 |
| Efficiency | ||||
| Inventory Turnover | 1.04 | 0.58 | 5.17 | 0.00 |
| Cash Conversion Cycle | 230.76 | 155.67 | -433.83 | 0.00 |